BEIJING and SUZHOU, China, Sept. 25, 2020 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, and its strategic partner CStone Pharmaceuticals (“CStone”, HKEX: 2616) today announced the launch of a multi-center clinical trial in China for the joint development of a companion diagnostic (CDx) test for avapritinib. This represents a key milestone in the companies’ collaboration. Avapritinib is a kinase inhibitor discovered by CStone’s partner Blueprint Medicines.
Genetron Health and CStone are jointly developing a CDx kit to detect the D842V mutation in the human platelet-derived growth factor receptor alpha (PDGFRA) gene using a polymerase chain reaction (PCR)-based method. The CDx test kit utilizes a real-time PCR fluorescent probe, combined with specific primers, Taqman probes, and highly specific Taq enzymes, to detect the mutation with